(Q38120296)

29 August 2017

title

Carfilzomib: a novel agent for multiple myeloma (English)

1 reference

29 August 2017

Kimberly Redic

1

1 reference

29 August 2017

publication date

24 April 2013

1 reference

Journal of Pharmacy and Pharmacology

29 August 2017

published in

1 reference

29 August 2017

volume

65

1 reference

29 August 2017

issue

8

1 reference

29 August 2017

page(s)

1095-1106

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

29 August 2017

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Epoxomicin, a new antitumor agent of microbial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

Clinical and investigational use of proteasome inhibitors for transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12072

21 January 2018

Identifiers

DOI

10.1111/JPHP.12072

1 reference

29 August 2017

1 reference